In order to give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all. What we do ...

In order to give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all. "What we do ...

This trial, which focused on anti-amyloid drugs, was set up in 2012 when the participants had either no symptoms or just mild cognitive symptoms. At this stage, they were within 15 years before to ...

Small study hints anti-amyloid therapy may keep Alzheimer’s symptoms at bay in certain patients By Brenda Goodman , CNN 11 minute read ...

In order to give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all. What we do ...

Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.

and Joanne Knight Distinguished Professor of Neurology at WashU Medicine, is the study director of an international clinical trial that finds an anti-amyloid drug can delay the onset of cognitive ...

The researchers have been testing amyloid-removing therapies in a group of people who have rare genetic mutations that make it almost certain they’ll develop Alzheimer’s.

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

The anti-amyloid therapy gantenerumab lowered the chances for developing Alzheimer’s-related dementia in people at high risk for the disease, according to a small study conducted by the Knight ...